Cargando…

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis

Prognostic modeling in myelofibrosis (MF) has classically pursued the integration of informative clinical and hematological parameters to separate patients' categories with different outcomes. Modern stratification includes also genetic data from karyotype and mutations. However, some poorly st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannelli, Francesco, Bencini, Sara, Coltro, Giacomo, Loscocco, Giuseppe G., Peruzzi, Benedetta, Rotunno, Giada, Maccari, Chiara, Gesullo, Francesca, Borella, Miriam, Paoli, Chiara, Caporale, Roberto, Mannarelli, Carmela, Annunziato, Francesco, Guglielmelli, Paola, Vannucchi, Alessandro M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682857/ https://www.ncbi.nlm.nih.gov/pubmed/35338671 http://dx.doi.org/10.1002/ajh.26548

Ejemplares similares

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF
por: Coltro, G., et al.
Publicado: (2022)

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2020)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Validation of the Mayo alliance prognostic system for mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2019)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells
por: Guglielmelli, Paola, et al.
Publicado: (2015)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Mannelli, Francesco, et al.
Publicado: (2023)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
por: Coltro, Giacomo, et al.
Publicado: (2023)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
por: Guglielmelli, P, et al.
Publicado: (2015)

Preanalytical conditions for multiparameter platelet flow cytometry
por: Hindle, Matthew S., et al.
Publicado: (2023)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
por: Fantini, Sebastian, et al.
Publicado: (2021)

Multiparameter Flow Cytometry: Advances in High Resolution Analysis
por: O'Donnell, Erika A, et al.
Publicado: (2013)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS
por: Sartini, S., et al.
Publicado: (2022)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells
por: Calura, E, et al.
Publicado: (2016)

Monitoring of population dynamics of Corynebacterium glutamicum by multiparameter flow cytometry
por: Neumeyer, Andrea, et al.
Publicado: (2013)

Current applications of multiparameter flow cytometry in plasma cell disorders
por: Jelinek, T, et al.
Publicado: (2017)

Current applications of multiparameter flow cytometry in plasma cell disorders
por: Jelinek, T, et al.
Publicado: (2018)

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category
por: Mannelli, Francesco, et al.
Publicado: (2020)

Diagnosis of Acute Leukemia by Multiparameter Flow Cytometry with the Assistance of Artificial Intelligence
por: Zhong, Pengqiang, et al.
Publicado: (2022)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
por: Barraco, Daniela, et al.
Publicado: (2018)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Contribution of Multiparameter Flow Cytometry Immunophenotyping to the Diagnostic Screening and Classification of Pediatric Cancer
por: Ferreira-Facio, Cristiane S., et al.
Publicado: (2013)

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis
por: Bianchi, Elisa, et al.
Publicado: (2017)

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
por: Vannucchi, Alessandro M., et al.
Publicado: (2020)

Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience
por: Capone, Manuela, et al.
Publicado: (2022)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
por: Zingariello, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8n0603oabl41t6mj1bhjr092uc